24 March 2021

Large-scale study aims at personalising medication in psychiatry

As many as two thirds of all psychiatric patients do not respond well to treatment with drugs. While compliance and frequent side effects play a major role, there are also genetic variations which determine whether serious side effects occur, and which can also prevent medication from working. An international consortium led by Dr Roos van Westrhenen (Maastricht University/Parnassia) is to conduct a pharmacogenomic study to establish the relationship between response to treatment and genetic background. The research was recently awarded eight million euros in European funding.